Respiratory medicine
-
Respiratory medicine · Feb 2012
Randomized Controlled Trial Multicenter StudyEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Treatment with an inhaled corticosteroid (ICS) and long-acting bronchodilator is recommended for severe/very severe chronic obstructive pulmonary disease (COPD) patients with repeated exacerbations. This randomized, double-blind, double-dummy, parallel-group, 12-month multicenter study evaluated the effect of budesonide/formoterol pressurized metered-dose inhaler (pMDI) on COPD exacerbations. ⋯ Over 12 months, both budesonide/formoterol doses reduced the exacerbation rate (defined with or without antibiotic treatment) versus formoterol. Budesonide/formoterol pMDI is an appropriate treatment for reducing exacerbations in COPD patients with a history of exacerbations. (NCT00419744).
-
Respiratory medicine · Oct 2011
Multicenter StudyQuality of spirometry tests performed by 9893 adults in 14 countries: the BOLD Study.
to determine the ability of participants in the Burden of Obstructive Lung Disease (BOLD) study to meet quality goals for spirometry test session quality and to assess factors contributing to good quality. ⋯ Quality goals for spirometry tests were met about 90% of the time in these population-based samples of adults from several countries.
-
Respiratory medicine · Sep 2011
Multicenter StudyEvaluating nocturnal oxygen desaturation in COPD--revised.
Although in patients with COPD, the approach to daytime hypoxemia using long-term oxygen therapy (LTOT) is established, the best approach to transient nocturnal desaturation varies among clinicians. An understanding of the prevalence of nocturnal desaturation in COPD, in the absence of other respiratory co-morbidities, is an important step towards its standardized management. ⋯ A significant proportion (38%) of patients with moderate-to-severe COPD who do not qualify for home oxygen therapy based on their daytime PaO(2) have nocturnal oxygen desaturation without evidence of sleep apnea. Home oximetry is an effective practical method for screening this population.
-
Respiratory medicine · Sep 2011
Randomized Controlled Trial Multicenter StudyEffect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease. A causal relationship between arterial stiffness and cardiovascular events has not been established, though their strong association raises the possibility that therapies that reduce arterial stiffness may improve cardiovascular outcomes. Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness in these patients. ⋯ FSC does not reduce aPWV in all patients with moderate to severe COPD, but may have effects in those with elevated arterial stiffness. Additional studies are required to determine if aPWV could serve as a surrogate for cardiovascular events in COPD.
-
Respiratory medicine · Aug 2011
Multicenter Study Clinical TrialClinical and radiographic correlates of hypoxemia and oxygen therapy in the COPDGene study.
Severe hypoxemia is a major complication of chronic obstructive pulmonary disease (COPD). Long-term oxygen therapy is beneficial in hypoxemic COPD patients. However, the clinical and radiographic predictors of hypoxemia and the use of oxygen therapy are not well described. This study aimed to find the correlates of resting hypoxemia and the pattern of oxygen use in moderate to severe COPD patients. ⋯ http://clinicaltrials.gov (NCT00608764).